President Biden signed the Inflation Reduction Act into law on August 16, 2022. Almost two years later, our panel will evaluate how the law has impacted rare disease research and development. Our expert panel will provide insights into how the Act's provisions could influence treatment affordability and availability for rare disease patients. Our panel will also touch on how to demonstrate the value of rare disease therapies in the space. This session is designed to spark a constructive dialogue among advocates, policymakers, and other stakeholders.